Sign In
Buy ATAI
$4.53
-0.280 (-5.82%)
At Close: Jun 03, 2026
atai Life Sciences entering catalyst-rich period with high-potential data readouts in 2025 and 2026
11:21am, Tuesday, 18'th Mar 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is entering a pivotal period with data from several key trials expected in 2025 and 2026, analysts at Jefferies have highlighted following the company's fourt
atai Life Sciences prepares for data readouts from key clinical trials, extends operational runway
09:31am, Monday, 17'th Mar 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said it saw significant progress in 2024 with key advancements in its clinical trials as it strengthened its financial position. The company successfully dose
atai Life Sciences doses first patient in Phase 2 treatment-resistant depression trial
09:40am, Tuesday, 11'th Mar 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that the first patient has been dosed in its Phase 2 Elumina trial of VLS-01, the company's oral transmucosal film formulation of DMT applied to the
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
07:00am, Tuesday, 11'th Mar 2025
- Elumina is a Phase 2, multicenter, double-blind, randomized, placebo-controlled, clinical trial to assess the efficacy, safety and tolerability of VLS-01 (buccal film DMT) in people suffering from t
atai Life Sciences-backed trial in treatment-resistant depression completes patient enrollment
08:46am, Wednesday, 05'th Mar 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that patient enrollment has been completed in Beckley Psytech's Phase 2b trial evaluating BPL-003 in treatment-resistant depression (TRD), with topl
Atai: Following The Path That Spravato Laid And Moving Beyond It
12:45pm, Thursday, 27'th Feb 2025
Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds. Standing on the shoulders of Johnson & Johnson's Spravato.
atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference
04:10pm, Monday, 24'th Feb 2025
NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of
Biotechs Highlight 6 Stocks Insiders Are Buying Now
08:45am, Sunday, 23'rd Feb 2025
Biotech companies saw the most notable insider purchases of the past week, including at the latest of the recent handful of biotech initial public offerings.
atai Life Sciences completes public offering, raising $63.25M
09:20am, Thursday, 20'th Feb 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) announced that it has closed is public offering of shares and the underwriter's option to purchase additional shares for gross proceeds of approximately $63.2
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
07:00am, Thursday, 20'th Feb 2025
NEW YORK and BERLIN, Feb. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment
atai Life Sciences announces pricing of $55M public offering of shares
08:40am, Thursday, 13'th Feb 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) said its registered underwritten offering of approximately 26.2 million shares will be priced at $2.10 per share to raise proceeds of $55 million. The underwr
atai Life Sciences Announces Pricing of Public Offering of Common Shares
10:47pm, Wednesday, 12'th Feb 2025
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment
atai Life Sciences unveils $55M public offering to advance mental health treatments
04:15pm, Wednesday, 12'th Feb 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has announced a proposed underwritten public offering of $55 million of its common shares. The company may also grant the underwriter a 30-day option to purch
atai Life Sciences Announces Proposed Public Offering of Common Shares
04:01pm, Wednesday, 12'th Feb 2025
NEW YORK and BERLIN, Feb. 12, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatmen
atai Life Sciences CEO discusses success of BPL-003 alcohol use disorder trial - ICYMI
01:46pm, Saturday, 08'th Feb 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) CEO Dr. Srinivas Rao joined Proactive to discuss promising results from Beckley Psytech's Phase 2a trial for BPL-003 in alcohol use disorder.
